AGMB
AgomAb Therapeutics NV American Depositary Shares (AGMB)
Healthcare • NASDAQ • $12.13+6.22%
- Symbol
- AGMB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $12.13
- Daily Change
- +6.22%
- Market Cap
- $597.38M
- Trailing P/E
- N/A
- Forward P/E
- -6.07
- 52W High
- $17.45
- 52W Low
- $9.00
- Analyst Target
- $32.00
- Dividend Yield
- N/A
- Beta
- N/A
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in pr…
Company websiteResearch AGMB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.